BioCentury | Jan 10, 2018
Preclinical News

Targeting cancer cell metabolism through circadian rhythm

...also noted that high NR1D2 expression in brain cancer patient tumor samples correlated with survival. Pelagos Pharmaceuticals Inc....
...BioCentury's BCIQ database, no other companies are developing NR1D1 and NR1D2 agonists for any indication. Allison Johnson Pelagos Pharmaceuticals Inc. Salk...
BioCentury | Sep 28, 2017
Translation in Brief

Bugs on the clock

...proteins in preclinical and clinical development for Type II diabetes, Cushing's disease and hepatic diseases. Pelagos Pharmaceuticals Inc....
BioCentury | Jan 4, 2016
Company News

Pelago Bioscience, AstraZeneca deal

Pelago and AstraZeneca partnered to develop assay formats and applications of the Cellular Thermal Shift Assay (CETSA) across the range of AZ’s therapeutic areas. Under the two-year, non-exclusive deal, the companies will collaborate on undisclosed...
BioCentury | Aug 8, 2013
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Measuring target engagement in samples An assay to detect ligand binding in cells could be used to assess target engagement during preclinical and clinical...
BioCentury | Aug 8, 2013
Cover Story

Engaging drug discovery

Determining whether a compound binds its intended target is a fundamental question in drug discovery, but assays for measuring target engagement in vivo can be indirect and inconclusive. To remedy the situation, a Swedish group...
Items per page:
1 - 5 of 5
BioCentury | Jan 10, 2018
Preclinical News

Targeting cancer cell metabolism through circadian rhythm

...also noted that high NR1D2 expression in brain cancer patient tumor samples correlated with survival. Pelagos Pharmaceuticals Inc....
...BioCentury's BCIQ database, no other companies are developing NR1D1 and NR1D2 agonists for any indication. Allison Johnson Pelagos Pharmaceuticals Inc. Salk...
BioCentury | Sep 28, 2017
Translation in Brief

Bugs on the clock

...proteins in preclinical and clinical development for Type II diabetes, Cushing's disease and hepatic diseases. Pelagos Pharmaceuticals Inc....
BioCentury | Jan 4, 2016
Company News

Pelago Bioscience, AstraZeneca deal

Pelago and AstraZeneca partnered to develop assay formats and applications of the Cellular Thermal Shift Assay (CETSA) across the range of AZ’s therapeutic areas. Under the two-year, non-exclusive deal, the companies will collaborate on undisclosed...
BioCentury | Aug 8, 2013
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Measuring target engagement in samples An assay to detect ligand binding in cells could be used to assess target engagement during preclinical and clinical...
BioCentury | Aug 8, 2013
Cover Story

Engaging drug discovery

Determining whether a compound binds its intended target is a fundamental question in drug discovery, but assays for measuring target engagement in vivo can be indirect and inconclusive. To remedy the situation, a Swedish group...
Items per page:
1 - 5 of 5